Journal Academy Formulary (JACF)

Eplontersen

Regulations: had been registered in the following countries: United States of America (USA).

Registration number (S.A.): Not available.

Insurance Drug Formulary (S.A.): Not available.

General Information:

Registered Company: Ionis Pharmaceuticals and AstraZeneca.

Regulatory Status: R.X.

Mechanism of Action: Plontersen, an antisense oligonucleotide-Ga1NAc conjugate, is structurally represented as [insert chemical structure here]. This drug causes degradation of mutant and wild-type transthyretin (TTR) mRNA through binding to the TTR mRNA.

Indication

Approved (Labeled) indication: Polyneuropathy due to amyloidosis, Hereditary transthyretin-mediated.

Dosage Forms: Injection.

Dosing/Administration: 45 mg subcutaneously once monthly.

Dose:

Dose in Renal/Hepatic Failure/Geriatric Dose: No dosage adjustment is needed.

Indicated for pediatrics: Safety and effectiveness not established in pediatric patients.

Pharmacokinetic:

Absorption

- Tmax,: 2 hours.

Distribution

- Vd: 12 L

Metabolism

- Hepatic

Excretion

Renal excretion: Less than 1% unchanged antisense oligonucleotide (ASO)

Elimination Half-Life

- SubQ: 3 week

Safety:

Common Adverse Reactions (%): Vomiting and vitamin A deficiency.

Severe/rare adverse Reactions (%) : Atrioventricular block.

Drug Interactions: Not reported yet.

Contraindications: Not available.

Precautions: Reduced serum vitamin A levels have been reported.

Monitoring Requirements: Not available.

Sound-Alikes/ Look-Alikes: Not available.

High Alert: Not available.

Boxed warnings or alerts issue: Not available.

Toxicity if antidote required: Not available.

Storage if there is a particular condition. Store in the original carton refrigerated between (2-8°C).

Patient counseling

- Report symptoms of vitamin A deficiency.
- Side effects may include vomiting, blurred vision and cataracts.

Cost Analysis

Drugs	Drug classes	Approval Indication	Dose	Cost (American Dollar)	Insurance drug formulary(SCHI)
Eplontersen	Antisense Oligonucleotide	Polyneuropathy due to amyloidosis, Hereditary transthyretin-mediated	45 mg subcutaneously once monthly	Around $500,000.	Not Covered (24.1.2024)

REFERENCES

1. U.S. Food and Drug Administration (FDA). Retrieved 21 December 2023.
2. International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 85". WHO Drug Information. 35 (1). hdl:10665/340684
3. Diep, John K.; Yu, Rosie Z.; Viney, Nicholas J.; Schneider, Eugene; Guo, Shuling; Henry, Scott; *et al.* (December 2022). "Population pharmacokinetic/pharmacodynamic modeling of eplontersen, an antisense oligonucleotide in development for transthyretin amyloidosis."
4. British Journal of Clinical Pharmacology. 88 (12): 5389–5398. doi:10.1111/bcp.15468

Juman Alsaab, Pharm D
Ministry of Health, Riyadh, SAUDI ARABIA.

Received: 03-02-2023;
Accepted: 07-04-2023.

Access this article online

www.ijpcs.net

DOI: 10.5530/ijpcs.2024.13.3